Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Fidoamore, Alessia ^a   Cristiano, Loredana ^a   Antonosante, Andrea ^a   D'Angelo, Michele ^a   Di Giacomo, Erica ^a   Astarita, Carlo ^b   Giordano, Antonio ^b,c   Ippoliti, Rodolfo ^a   Benedetti, Elisabetta ^a   Cimini, Annamaria ^a,b,d  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b TEMPLE UNIVERSITY   (United States)

^c UNIVERSITY OF SIENA   (Italy)

^d LABORATORI NAZIONALI DEL GRAN SASSO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 8; PIGMENT EPITHELIUM DERIVED FACTOR; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CARCINOGENICITY; CELL HYPOXIA; CELL SELF-RENEWAL; CELL SURVIVAL; CHEMORADIOTHERAPY; EXTRACELLULAR MATRIX; GLIOBLASTOMA; GLIOMA CELL; HUMAN; METASTASIS; MICROENVIRONMENT; MICROVASCULATURE; NONHUMAN; OXYGEN TENSION; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIVITY; STEM CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84961341005     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/6809105     Document Type: Article

References (206)

1. T. Lapidot, C. Sirard, J. Vormoor et al., "A cell initiating human acute myeloid leukaemia after transplantation into SCID mice," Nature, vol. 367, no. 6464, pp. 645-648, 1994.
2. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J.Morrison, and M. F. Clarke, "Prospective identification of tumorigenic breast cancer cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 3983-3988, 2003.
3. C. F. Bender Kim, E. L. Jackson, A. E. Woolfenden et al., "Identification of bronchioalveolar stem cells in normal lung and lung cancer," Cell, vol. 121, no. 6, pp. 823-835, 2005.
4. A. T. Collins, P. A. Berry, C. Hyde, M. J. Stower, and N. J. Maitland, "Prospective identification of tumorigenic prostate cancer stem cells," Cancer Research, vol. 65, no. 23, pp. 10946-10951, 2005.
5. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, "A human colon cancer cell capable of initiating tumour growth in immunodeficient mice," Nature, vol. 445, no. 7123, pp. 106-110, 2007.
6. H. D. Hemmati, I. Nakano, J. A. Lazareff et al., "Cancerous stem cells can arise from pediatric brain tumors," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 15178-15183, 2003.
7. S. K. Singh, I. D. Clarke,M. Terasaki et al., "Identification of a cancer stem cell in human brain tumors," Cancer Research, vol. 63, no. 18, pp. 5821-5828, 2003.
8. B. A. Reynolds and S. Weiss, "Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system," Science, vol. 255, no. 5052, pp. 1707-1710, 1992.
9. P. S. Eriksson, E. Perfilieva,T. Björk-Eriksson et al., "Neurogenesis in the adult human hippocampus," Nature Medicine, vol. 4, no. 11, pp. 1313-1317, 1998.
10. G.-L.Ming and H. Song, "Adult neurogenesis in themammalian central nervous system," Annual Review of Neuroscience, vol. 28, pp. 223-250, 2005.
11. A. L. Vescovi, R. Galli, and B. A. Reynolds, "Brain tumour stem cells," Nature Reviews Cancer, vol. 6, no. 6, pp. 425-436, 2006.
12. T. N. Ignatova, V. G. Kukekov, E. D. Laywell, O. N. Suslov, F. D. Vrionis, and D. A. Steindler, "Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronalmarkers in vitro," Glia, vol. 39,no. 3, pp. 193-206, 2002.
13. T. Kondo, T. Setoguchi, and T. Taga, "Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 3, pp. 781-786, 2004.
14. R. Galli, E. Binda, U. Orfanelli et al., "Isolation and characterization of tumorigenic, stem-like neural precursors fromhuman glioblastoma," Cancer Research, vol. 64, no. 19, pp. 7011-7021, 2004.
15. S. K. Singh, C. Hawkins, I. D. Clarke et al., "Identification of human brain tumour initiating cells," Nature, vol. 432, no. 7015, pp. 396-401, 2004.
16. X. P. Yuan, J. Curtin, Y. Xiong et al., "Isolation of cancer stem cells from adult glioblastomamultiforme,"Oncogene, vol. 23,no. 58, pp. 9392-9400, 2004.
17. D. Beier, P. Hau, M. Proescholdt et al., "CD133+ and CD133? glioblastoma-derived cancer stem cells showdifferential growth characteristics and molecular profiles," Cancer Research, vol. 67, no. 9, pp. 4010-4015, 2007.
18. M. J. Son,K.Woolard,D.-H. Nam, J. Lee, andH.A.Fine, "SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma," Cell Stem Cell, vol. 4, no. 5, pp. 440-452, 2009.
19. V. Clément, D.Marino, C. Cudalbu et al., "Marker-independent identification of glioma-initiating cells," Nature Methods, vol. 7, no. 3, pp. 224-228, 2010.
20. S. K. Singh, I. D. Clarke, T. Hide, and P. B. Dirks, "Cancer stem cells in nervous system tumors," Oncogene, vol. 23, no. 43, pp. 7267-7273, 2004.
21. E. C.Holland, J. Celestino, C.Dai, L. Schaefer, R. E. Sawaya, and G. N. Fuller, "Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice," Nature Genetics, vol. 25, no. 1, pp. 55-57, 2000.
22. S. Alcantara Llaguno, J. Chen, C.-H. Kwon et al., "Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model," Cancer Cell, vol. 15, no. 1, pp. 45-56, 2009.
23. Y. Wang, J. Yang, H. Zheng et al., "Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model," Cancer Cell, vol. 15, no. 6, pp. 514-526, 2009.
24. N. Lindberg, M. Kastemar, T. Olofsson, A. Smits, and L. Uhrbom, "Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma," Oncogene, vol. 28, no. 23, pp. 2266-2275, 2009.
25. C. Liu, J. C. Sage, M. R. Miller et al., "Mosaic analysis with double markers reveals tumor cell of origin in glioma," Cell, vol. 146, no. 2, pp. 209-221, 2011.
26. H. Koso, H. Takeda, C. C. K. Yew et al., "Transposonmutagenesis identifies genes that transformneural stemcells into gliomainitiating cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 44, pp. E2998-E3007, 2012.
27. C. Dai, J. C. Celestino, Y. Okada, D. N. Louis, G. N. Fuller, and E. C. Holland, "PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas from and oligoastrocytomas neural progenitors and astrocytes in vivo," Genes and Development, vol. 15, no. 15, pp. 1913-1925, 2001.
28. T. Marumoto, A. Tashiro, D. Friedmann-Morvinski et al., "Development of a novelmouse glioma model using lentiviral vectors," Nature Medicine, vol. 15, no. 1, pp. 110-116, 2009.
29. H. Zheng, H. Ying, H. Yan et al., "p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation," Nature, vol. 455, no. 7216, pp. 1129-1133, 2008.
30. T. S. Jacques, A. Swales, M. J. Brzozowski et al., "Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes," The EMBO Journal, vol. 29, no. 1, pp. 222-235, 2010.
31. R. M. Bachoo, E. A. Maher, K. L. Ligon et al., "Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis," Cancer Cell, vol. 1, no. 3, pp. 269-277, 2002.
32. S. W. M. Bruggeman, D. Hulsman, E. Tanger et al., "Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma," Cancer Cell, vol. 12, no. 4, pp. 328-341, 2007.
33. L. Uhrbom, C. Dai, J. C. Celestino, M. K. Rosenblum, G. N. Fuller, and E. C. Holland, "Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt," Cancer Research, vol. 62, no. 19, pp. 5551-5558, 2002.
34. L. Uhrbom, M. Kastemar, F. K. Johansson, B. Westermark, and E. C. Holland, "Cell type-specific tumor suppression by Ink4a and Arf in kras-induced mouse gliomagenesis," Cancer Research, vol. 65, no. 6, pp. 2065-2069, 2005.
35. L. C. Fuentealba, K. Obernier, and A. Alvarez-Buylla, "Adult neural stem cells bridge their niche," Cell Stem Cell, vol. 10, no. 6, pp. 698-708, 2012.
36. N. Sanai, A. Alvarez-Buylla, and M. S. Berger, "Mechanisms of disease: neural stem cells and the origin of gliomas," The New England Journal of Medicine, vol. 353, no. 8, pp. 811-822, 2005.
37. X. Fan, L. G. Salford, and B. Widegren, "Glioma stem cells: evidence and limitation," Seminars in Cancer Biology, vol. 17, no. 3, pp. 214-218, 2007.
38. A. S.Modrek, N. S. Bayin, and D. G. Placantonakis, "Brain stem cells as the cell of origin in glioma,"World Journal of Stem Cells, vol. 6, no. 1, pp. 43-52, 2014.
39. T. Reya, S. J. Morrison,M. F. Clarke, and I. L.Weissman, "Stem cells, cancer, and cancer stem cells," Nature, vol. 414, no. 6859, pp. 105-111, 2001.
40. M. Z. Ratajczak, "Cancer stem cells-normal stem cells 'Jedi' that went over to the 'dark side'," Folia Histochemica et Cytobiologica, vol. 43, no. 4, pp. 175-181, 2005.
41. A. Mohyeldin, T. Garzón-Muvdi, and A. Quiñones-Hinojosa, "Oxygen in stem cell biology: a critical component of the stem cell niche," Cell Stem Cell, vol. 7, no. 2, pp. 150-161, 2010.
42. F. Doetsch, "A niche for adult neural stem cells," Current Opinion in Genetics & Development, vol. 13, no. 5, pp. 543-550, 2003.
43. J. J. Ohab, S. Fleming, A. Blesch, and S. T. Carmichael, "A neurovascular niche for neurogenesis after stroke," The Journal of Neuroscience, vol. 26, no. 50, pp. 13007-13016, 2006.
44. M. Tavazoie, L. Van der Veken, V. Silva-Vargas et al., "A specialized vascular niche for adult neural stem cells," Cell Stem Cell, vol. 3, no. 3, pp. 279-288, 2008.
45. D. J. Brat, B. Kaur, and E. G. VanMeir, "Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors," Frontiers in Bioscience, vol. 8, pp. d100-d116, 2003.
46. P. Vaupel, F. Kallinowski, and P. Okunieff, "Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review," Cancer Research, vol. 49, no. 23, pp. 6449-6465, 1989.
47. P. Vaupel, "The role of hypoxia-induced factors in tumor progression," The Oncologist, vol. 9, no. 5, pp. 10-17, 2004.
48. S.M. Evans,K.D. Judy, I. Dunphy et al., "Hypoxia is important in the biology and aggression of human glial brain tumors," Clinical Cancer Research, vol. 10, no. 24, pp. 8177-8184, 2004.
49. S. M. Evans, K. D. Judy, I. Dunphy et al., "Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding," Cancer Research, vol. 64, no. 5, pp. 1886-1892, 2004.
50. S. M. Evans, K. W. Jenkins, W. T. Jenkins et al., "Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human brain tumors," Radiation Research, vol. 170, no. 6, pp. 677-690, 2008.
51. J.M. Heddleston, Z. Li, J. D. Lathia, S. Bao, A. B. Hjelmeland, and J. N. Rich, "Hypoxia inducible factors in cancer stem cells," British Journal of Cancer, vol. 102, no. 5, pp. 789-795, 2010.
52. R. L. Jensen, "Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target," Journal of Neuro-Oncology, vol. 92, no. 3, pp. 317-335, 2009.
53. P. Vaupel, A. Mayer, and M. Höckel, "Tumor hypoxia and malignant progression," Methods in Enzimology, vol. 381, pp. 335-354, 2004.
54. L. H. Gray, A. D. Conger, M. Ebert, S. Hornsey, and O. C. Scott, "The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy," The British Journal of Radiology, vol. 26, no. 312, pp. 638-648, 1953.
55. A. M. Spence, M. Muzi, K. R. Swanson et al., "Regional hypoxia in glioblastoma multiforme quantified with [18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival," Clinical Cancer Research, vol. 14, no. 9, pp. 2623-2630, 2008.
56. H.Matsumoto, A. Takahashi, and T.Ohnishi, "Nitric oxide radicals choreograph a radioadaptive response," Cancer Research, vol. 67, no. 18, pp. 8574-8579, 2007.
57. G.-Y. Liou and P. Storz, "Reactive oxygen species in cancer," Free Radical Research, vol. 44, no. 5, pp. 479-496, 2010.
58. N. A. Riobó, E. Clementi,M.Melani et al., "Nitric oxide inhibits mitochondrial NADH:ubiquinone reductase activity through peroxynitrite formation," Biochemical Journal, vol. 359, no. 1, pp. 139-145, 2001.
59. C. S. Cobbs, M. Samanta, L. E. Harkins, G. Y. Gillespie, B. A. Merrick, and L. A. MacMillan-Crow, "Evidence for peroxynitrite-mediated modifications to p53 in human gliomas: possible functional consequences," Archives of Biochemistry and Biophysics, vol. 394, no. 2, pp. 167-172, 2001.
60. C. S. Cobbs, T. R.Whisenhunt, D. R.Wesemann, L. E. Harkins, E. G. Van Meir, and M. Samanta, "Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells," Cancer Research, vol. 63, no. 24, pp. 8670-8673, 2003.
61. P. A. Schomack and R. J. Gillies, "Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors," Neoplasia, vol. 5, no. 2, pp. 135-145, 2003.
62. Y. Kato, S. Ozawa, C. Miyamoto et al., "Acidic extracellular microenvironment and cancer," Cancer Cell International, vol. 13, no. 1, article 89, 2013.
63. D. Fukumura, L. Xu, Y. Chen, T. Gohongi, B. Seed, and R. K. Jain, "Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo," Cancer Research, vol. 61, no. 16, pp. 6020-6024, 2001.
64. L. Xu, D. Fukumura, and R. K. Jain, "Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in humanglioblastoma cells viaERK1/2MAPKsignalingpathway: mechanismof lowpH-inducedVEGF," The Journal of Biological Chemistry, vol. 277, no. 13, pp. 11368-11374, 2002.
65. J. Chiche, M. C. Brahimi-Horn, and J. Pouysségur, "Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer," Journal of Cellular and Molecular Medicine, vol. 14, no. 4, pp. 771-794, 2010.
66. M. Reichert, J. P. Steinbach, P. Supra, and M. Weller, "Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis," Cancer, vol. 95, no. 5, pp. 1113-1119, 2002.
67. T. Mashima, S. Sato, Y. Sugimoto, T. Tsuruo, and H. Seimiya, "Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions," Oncogene, vol. 28, no. 1, pp. 9-19, 2009.
68. O. Trédan, C. M. Galmarini, K. Patel, and I. F. Tannock, "Drug resistance and the solid tumor microenvironment," Journal of the National Cancer Institute, vol. 99, no. 19, pp. 1441-1454, 2007.
69. C.-H.Heldin, K. Rubin, K. Pietras, and A. Ostman, "High interstitial fluid pressure-an obstacle in cancer therapy," Nature Reviews Cancer, vol. 4, no. 10, pp. 806-813, 2004.
70. J. D. Lathia, J. M. Heddleston, M. Venere, and J. N. Rich, "Deadly teamwork: neural cancer stem cells and the tumor microenvironment," Cell Stem Cell, vol. 8, no. 5, pp. 482-485, 2011.
71. E. E. Bar, A. Lin, V. Mahairaki, W. Matsui, and C. G. Eberhart, "Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres," The American Journal of Pathology, vol. 177, no. 3, pp. 1491-1502, 2010.
72. S. Seidel, B. K. Garvalov, V. Wirta et al., "A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2," Brain, vol. 133, no. 4, pp. 983-995, 2010.
73. D. T. Scadden, "The stem-cell niche as an entity of action," Nature, vol. 441, no. 7097, pp. 1075-1079, 2006.
74. E. Binello and I. M. Germano, "Targeting glioma stem cells: a novel framework for brain tumors," Cancer Science, vol. 102, no. 11, pp. 1958-1966, 2011.
75. C. Calabrese, H. Poppleton, M. Kocak et al., "A perivascular niche for brain tumor stem cells," Cancer Cell, vol. 11, no. 1, pp. 69-82, 2007.
76. M.D. Brooks,R. Sengupta, S. C. Snyder, and J. B.Rubin, "Hitting them where they live: targeting the glioblastoma perivascular stem cell niche," Current Pathobiology Reports, vol. 1, no. 2, pp. 101-110, 2013.
77. R. J. Gilbertson and J. N. Rich, "Making a tumour's bed: glioblastoma stem cells and the vascular niche," Nature Reviews Cancer, vol. 7, no. 10, pp. 733-736, 2007.
78. S. Bao, Q. Wu, S. Sathornsumetee et al., "Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor," Cancer Research, vol. 66, no. 16, pp. 7843-7848, 2006.
79. G.-N. Yan, L. Yang, Y.-F. Lv et al., "Endothelial cells promote stem-like phenotype of glioma cells through activating the Hedgehog pathway," The Journal of Pathology, vol. 234, no. 1, pp. 11-22, 2014.
80. L. Ricci-Vitiani, R. Pallini, M. Biffoni et al., "Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells," Nature, vol. 477, no. 7363, p. 238, 2010.
81. R.Wang, K. Chadalavada, J.Wilshire et al., "Glioblastoma stemlike cells give rise to tumour Endothelium," Nature, vol. 468, no. 7325, pp. 829-833, 2010.
82. M. Garcia-Barros, F. Paris, C. Cordon-Cardo et al., "Tumor response to radiotherapy regulated by endothelial cell apoptosis," Science, vol. 300, no. 5622, pp. 1155-1159, 2003.
83. C. K. Brown, N. N. Khodarev, J. Yu et al., "Glioblastoma cells block radiation-induced programmed cell death of endothelial cells," FEBS Letters, vol. 565, no. 1-3, pp. 167-170, 2004.
84. O. Casanovas, D. J. Hicklin, G. Bergers, and D. Hanahan, "Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors," Cancer Cell, vol. 8, no. 4, pp. 299-309, 2005.
85. T. T. Batchelor,A.G. Sorensen, E. di Tomaso et al., "AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients," Cancer Cell, vol. 11, no. 1, pp. 83-95, 2007.
86. Y. Shaked, T. Tang, J. Woloszynek et al., "Contribution of granulocyte colony-stimulating factor to the acutemobilization of endothelial precursor cells by vascular disrupting agents," Cancer Research, vol. 69, no. 19, pp. 7524-7528, 2009.
87. S. Scully, R. Francescone,M. Faibish et al., "Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas," The Journal of Neuroscience, vol. 32, no. 37, pp. 12950-12960, 2012.
88. J. F. de Groot, G. Fuller, A. J. Kumar et al., "Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice," Neuro-Oncology, vol. 12, no. 3, pp. 233-242, 2010.
89. O. Keunen, M. Johansson, A. Oudin et al., "Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 9, pp. 3749-3754, 2011.
90. L. Sun, A.-M. Hui, Q. Su et al., "Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain," Cancer Cell, vol. 9, no. 4, pp. 287-300, 2006.
91. A. Erlandsson, J. Larsson, and K. Forsberg-Nilsson, "Stem cell factor is a chemoattractant and a survival factor for CNS stem cells," Experimental Cell Research, vol. 301, no. 2, pp. 201-210, 2004.
92. K. Jin, X.O.Mao, Y. Sun, L. Xie, and D. A. Greenberg, "Stem cell factor stimulates neurogenesis in vitro and in vivo," The Journal of Clinical Investigation, vol. 110, no. 3, pp. 311-319, 2002.
93. K. Pumiglia and S. Temple, "PEDF: bridging neurovascular interactions in the stem cell niche," Nature Neuroscience, vol. 9, no. 3, pp. 299-300, 2006.
94. C. Ramrez-Castillejo, F. Sánchez-Sánchez, C. Andreu-Agulló et al., "Pigment epithelium-derived factor is a niche signal for neural stem cell renewal," Nature Neuroscience, vol. 9, no. 3, pp. 331-339, 2006.
95. C. Andreu-Agulló, J. M. Morante-Redolat, A. C. Delgado, and I. Faras, "Vascular niche factor PEDF modulates notchdependent stemness in the adult subependymal zone," Nature Neuroscience, vol. 12, no. 12, pp. 1514-1523, 2009.
96. N. Bouck, "PEDF: anti-angiogenic guardian of ocular function," Trends in Molecular Medicine, vol. 8, no. 7, pp. 330-334, 2002.
97. S. Halin, P. Wikström, S. H. Rudolfsson et al., "Decreased pigment epithelium-derived factor is associated withmetastatic phenotype in human and rat prostate tumors," Cancer Research, vol. 64, no. 16, pp. 5664-5671, 2004.
98. H. Uehara, M. Miyamoto, K. Kato et al., "Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma," Cancer Research, vol. 64, no. 10, pp. 3533-3537, 2004.
99. M. Guan, H.-F. Yam, B. Su et al., "Loss of pigment epithelium derived factor expression in glioma progression," Journal of Clinical Pathology, vol. 56, no. 4, pp. 277-282, 2003.
100. D. M. Sidle, J. Maddalozzo, J. D. Meier, M. Cornwell, V. Stellmach, and S. E. Crawford, "Altered pigment epitheliumderived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence," Archives of Otolaryngology-Head and Neck Surgery, vol. 131, no. 11, pp. 990-995, 2005.
101. S. E. Crawford, V. Stellmach, M. Ranalli et al., "Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctionalmediator of Schwann cell antitumor activity," Journal of Cell Science, vol. 114, no. 24, pp. 4421-4428, 2001.
102. J. Yin, G. Park, T. H. Kim et al., "Pigment Epithelium-Derived Factor (PEDF) expression induced by EGFRvIII promotes selfrenewal and tumor progression of glioma stem cells," PLoS Biology, vol. 13, no. 5, Article IDe1002152, 2015.
103. R. B. Maksym, M. Tarnowski, K. Grymula et al., "The role of stromal derived factor-1-CXCR7 axis in development and cancer," European Journal of Pharmacology, vol. 625, no. 1-3, pp. 31-40, 2009.
104. A. Bajetto, F. Barbieri, A. Pattarozzi et al., "CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumoral meningothelial cells in vitro," Neuro-Oncology, vol. 9, no. 1, pp. 3-11, 2007.
105. F. Barbieri, A. Bajetto, R. Stumm et al., "Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas," Clinical Cancer Research, vol. 14, no. 16, pp. 5022-5032, 2008.
106. F. Barbieri, A. Bajetto, and T. Florio, "Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target," Journal of Oncology, vol. 2010, Article ID426956, 15 pages, 2010.
107. F. Barbieri, A. Bajetto, A. Pattarozzi et al., "The chemokine SDF1/CXCL12: a novel autocrine/paracrine factor involved in pituitary adenoma development," Open Neuroendocrinology Journal, vol. 4, no. 1, pp. 64-76, 2011.
108. A.Müller, B. Homey, H. Soto et al., "Involvement of chemokine receptors in breast cancer metastasis," Nature, vol. 410, no. 6824, pp. 50-56, 2001.
109. A. Bajetto, F. Barbieri, A. Dorcaratto et al., "Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferationand migration," Neurochemistry International, vol. 49,no. 5, pp.423-432, 2006.
110. S. Barbero, R. Bonavia, A. Bajetto et al., "Stromal cell-derived factor 1 stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt," Cancer Research, vol. 63, no. 8, pp. 1969-1974, 2003.
111. J. B. Rubin, A. L. Kung, R. S. Klein et al., "A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 23, pp. 13513-13518, 2003.
112. K. Balabanian, B. Lagane, S. Infantino et al., "The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes," The Journal of Biological Chemistry, vol. 280, no. 42, pp. 35760-35766, 2005.
113. J.M. Burns, B. C. Summers, Y.Wang et al., "A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development,"The Journal of Experimental Medicine, vol. 203, no. 9, pp. 2201-2213, 2006.
114. X. Sun, G. Cheng, M. Hao et al., "CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression," Cancer Metastasis Reviews, vol. 29, no. 4, pp. 709-722, 2010.
115. A. Orimo, P. B. Gupta, D. C. Sgroi et al., "Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion," Cell, vol. 121, no. 3, pp. 335-348, 2005.
116. M. Ehtesham, K. Y. Mapara, C. B. Stevenson, and R. C. Thompson, "CXCR4 mediates the proliferation of glioblastoma progenitor cells," Cancer Letters, vol. 274, no. 2, pp. 305-312, 2009.
117. C. Folkins, Y. Shaked, S. Man et al., "Glioma tumor stemlike cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1," Cancer Research, vol. 69, no. 18, pp. 7243-7251, 2009.
118. M. Gatti, A. Pattarozzi, A. Bajetto et al., "Inhibition of CXCL12/ CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity," Toxicology, vol. 314, no. 2-3, pp. 209-220, 2013.
119. R. Würth, A. Bajetto, J. K. Harrison, F. Barbieri, and T. Florio, "CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment," Frontiers in Cellular Neuroscience, vol. 8, article 144, 19 pages, 2014.
120. B. Boldajipour,H.Mahabaleshwar, E. Kardash et al., "Control of chemokine-guided cell migration by ligand sequestration," Cell, vol. 132, no. 3, pp. 463-473, 2008.
121. M. Thelen and S. Thelen, "CXCR7, CXCR4 and CXCL12: an eccentric trio?" Journal of Neuroimmunology, vol. 198, no. 1-2, pp. 9-13, 2008.
122. K.Hattermann, J.Held-Feindt, R. Lucius et al., "The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects," Cancer Research, vol. 70, no. 8, pp. 3299-3308, 2010.
123. R. Du, K. V. Lu, C. Petritsch et al., "HIF1 induces the recruitment of bonemarrow-derived vascularmodulatory cells to regulate tumor angiogenesis and invasion," Cancer Cell, vol. 13, no. 3, pp. 206-220, 2008.
124. M. De Palma, M. A. Venneri, R. Galli et al., "Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors," Cancer Cell, vol. 8, no. 3, pp. 211-226, 2005.
125. D. K. Jin, K. Shido, H.-G. Kopp et al., "Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes," Nature Medicine, vol. 12, no. 5, pp. 557-567, 2006.
126. S. A. Rempel, S.Dudas, S.Ge, andJ.A.Gutiérrez, "Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma," Clinical Cancer Research, vol. 6, no. 1, pp. 102-111, 2000.
127. D. Zagzag, M. Esencay,O.Mendez et al., "Hypoxia-and vascular endothelial growth factor-induced stromal cell-derived factor-1/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures," The American Journal of Pathology, vol. 173, no. 2, pp. 545-560, 2008.
128. S. Rao, R. Sengupta, E. J. Choe et al., "CXCL12 mediates trophic interactions between endothelial and tumor cells in glioblastoma," PLoS ONE, vol. 7, no. 3,Article ID e33005, 2012.
129. Y. Sonoda, T. Ozawa, K. D. Aldape, D. F. Deen, M. S. Berger, and R. O. Pieper, "Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma," Cancer Research, vol. 61, no. 18, pp. 6674-6678, 2001.
130. G. Helbig, K.W. Christopherson, P. Bhat-Nakshatri et al., "NF-B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4," The Journal of Biological Chemistry, vol. 278, no. 24, pp. 21631-21638, 2003.
131. C.-Y. Wang, M. W. Mayo, and A. S. Baldwin Jr., "TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-B," Science, vol. 274, no. 5288, pp. 784-787, 1996.
132. T.N.Hartmann, J. A. Burger,A.Glodek,N. Fujii, and M. Burger, "CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells," Oncogene, vol. 24, no. 27, pp. 4462-4471, 2005.
133. T. Sethi, R. C. Rintoul, S. M. Moore et al., "Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo," Nature Medicine, vol. 5, no. 6, pp. 662-668, 1999.
134. D. G. Duda, S. V. Kozin, N. D. Kirkpatrick, L. Xu, D. Fukumura, and R. K. Jain, "CXCL12 (SDF1)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?" Clinical Cancer Research, vol. 17, no. 8, pp. 2074-2080, 2011.
135. S. Hiratsuka, D. G. Duda, Y. Huang et al., "C-X-C receptor type 4 promotesmetastasis by activating p38 mitogen-activated protein kinase inmyeloid differentiation antigen (Gr-1)-positive cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 1, pp. 302-307, 2011.
136. S. V. Kozin, W. S. Kamoun, Y. Huang, M. R. Dawson, R. K. Jain, and D. G. Duda, "Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation," Cancer Research, vol. 70, no. 14, pp. 5679-5685, 2010.
137. Y. Shaked, E. Henke, J. M. L. Roodhart et al., "Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents," Cancer Cell, vol. 14, no. 3, pp. 263-273, 2008.
138. C. C. Chang, O. Z. Lerman, V. D. Thanik et al., "Dose-dependent effect of radiation on angiogenic and angiostatic CXC chemokine expression in human endothelial cells," Cytokine, vol. 48, no. 3, pp. 295-302, 2009.
139. N. Redjal, J. A. Chan, R. A. Segal, and A. L. Kung, "CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas," Clinical Cancer Research, vol. 12, no. 22, pp. 6765-6771, 2006.
140. L. Ellis and D. J. Hicklin, "Pathways mediating resistance to vascular endothelial growth factor-targeted therapy," Clinical Cancer Research, vol. 14, no. 20, pp. 6371-6375, 2008.
141. D. A. Reardon, P. Y. Wen, A. Desjardins, T. T. Batchelor, and J. J. Vredenburgh, "Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy," Expert Opinion on Biological Therapy, vol. 8, no. 4, pp. 541-553, 2008.
142. W. J. Kil, P. J. Tofilon, and K. Camphausen, "Post-radiation increase in VEGF enhances glioma cell motility in vitro," Radiation Oncology, vol. 7, no. 1, article 25, 2012.
143. D. J. Brat, A. C. Bellail, and E. G. Van Meir, "The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis," Neuro-Oncology, vol. 7, no. 2, pp. 122-133, 2005.
144. V. F. Zhu, J. Yang, D. G. LeBrun, and M. Li, "Understanding the role of cytokines in GlioblastomaMultiforme pathogenesis," Cancer Letters, vol. 316, no. 2, pp. 139-150, 2012.
145. E. Van Meir, M. Ceska, F. Effenberger et al., "Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system," Cancer Research, vol. 52, no. 16, pp. 4297-4305, 1992.
146. B. Raychaudhuri and M. A. Vogelbaum, "IL-8 is a mediator of NF-B induced invasion by gliomas," Journal of Neuro-Oncology, vol. 101, no. 2, pp. 227-235, 2011.
147. A. Li, S. Dubey, M. L. Varney, B. J. Dave, and R. K. Singh, "IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis," The Journal of Immunology, vol. 170, no. 6, pp. 3369-3376, 2003.
148. C. Ginestier, S. Liu, M. E. Diebel et al., "CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts,"The Journal of Clinical Investigation, vol. 120, no. 2, pp. 485-497, 2010.
149. K. H. Tang, S. Ma, T. K. Lee et al., "CD133+ liver tumorinitiating cells promote tumor angiogenesis, growth, and selfrenewal through neurotensin/interleukin-8/CXCL1 signaling," Hepatology, vol. 55, no. 3, pp. 807-820, 2012.
150. D.W. Infanger, Y. Cho, B. S. Lopez et al., "Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche," Cancer Research, vol. 73, no. 23, pp. 7079-7089, 2013.
151. S. Y. Park, J. Han, J. B. Kim et al., "Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma," European Journal of Cancer, vol. 50, no. 2, pp. 341-350, 2014.
152. F. Pistollato, S. Abbadi, E. Rampazzo et al., "Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma," Stem Cells, vol. 28, no. 5, pp. 851-862, 2010.
153. L. Yang, C. Lin, L. Wang, H. Guo, and X. Wang, "Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications," Experimental Cell Research, vol. 318, no. 19, pp. 2417-2426, 2012.
154. E. B. Rankin and A. J. Giaccia, "The role of hypoxia-inducible factors in tumorigenesis," Cell Death and Differentiation, vol. 15, no. 4, pp. 678-685, 2008.
155. G. L. Semenza, "Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics," Oncogene, vol. 29, no. 5, pp. 625-634, 2010.
156. G. L. Semenza, "HIF-1 mediates metabolic responses to intratumoral hypoxia andoncogenicmutations,"The Journal of Clinical Investigation, vol. 123, no. 9, pp. 3664-3671, 2013.
157. L. Persano, E. Rampazzo, G. Basso, and G. Viola, "Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting," Biochemical Pharmacology, vol. 85, no. 5, pp. 612-622, 2013.
158. D. J. Brat, A. A. Castellano-Sanchez, S. B. Hunter et al., "Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population," Cancer Research, vol. 64, no. 3, pp. 920-927, 2004.
159. D. Zagzag, H. Zhong, J. M. Scalzitti, E. Laughner, J.W. Simons, and G. L. Semenza, "Expression of hypoxia-inducible factor 1 in brain tumors: association with angiogenesis, invasion, and progression," Cancer, vol. 88, no. 11, pp. 2606-2618, 2000.
160. B. A. Teicher, "Hypoxia and drug resistance," Cancer and Metastasis Reviews, vol. 13, no. 2, pp. 139-168, 1994.
161. B. J. Moeller, Y. Cao, C. Y. Li, and M. W. Dewhirst, "Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules," Cancer Cell, vol. 5, no. 5, pp. 429-441, 2004.
162. F. H. Hochberg and A. Pruitt, "Assumptions in the radiotherapy of glioblastoma," Neurology, vol. 30, no. 9, pp. 907-911, 1980.
163. F. Mornex, H. Nayel, and L. Taillandier, "Radiation therapy for malignant astrocytomas in adults," Radiotherapy and Oncology, vol. 27, no. 3, pp. 181-192, 1993.
164. A. S. Garden, M. H. Maor, W. K. Alfred Yung et al., "Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas," Radiotherapy and Oncology, vol. 20, no. 2, pp. 99-110, 1991.
165. C. F. Hess, J. C. Schaaf, R. D. Kortmann, M. Schabet, and M. Bamberg, "Malignant glioma: patterns of failure following individually tailored limited volume irradiation," Radiotherapy and Oncology, vol. 30, no. 2, pp. 146-149, 1994.
166. N. Rohwer and T. Cramer, "Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways," Drug Resistance Updates, vol. 14, no. 3, pp. 191-201, 2011.
167. P. Lu, V. M. Weaver, and Z. Werb, "The extracellular matrix: a dynamic niche in cancer progression," The Journal of Cell Biology, vol. 196, no. 4, pp. 395-406, 2012.
168. M. Mannino and A. J. Chalmers, "Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'?" Molecular Oncology, vol. 5, no. 4, pp. 374-386, 2011.
169. J. Y. Ljubimova,M. Fugita, N. M. Khazenzon et al., "Association between laminin-8 and glial tumor grade, recurrence, and patient survival," Cancer, vol. 101, no. 3, pp. 604-612, 2004.
170. P. Huang, M. R. S. Rani, M. S. Ahluwalia et al., "Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin 61 in glioblastoma," Cancer Research, vol. 72, no. 6, pp. 1428-1437, 2012.
171. T. M. Fael Al-Mayhani, S. L. R. Ball, J.-W. Zhao et al., "An efficientmethod for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours," Journal of Neuroscience Methods, vol. 176, no. 2, pp. 192-199, 2009.
172. S. M. Pollard, K. Yoshikawa, I. D. Clarke et al., "Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens," Cell Stem Cell, vol. 4, no. 6, pp. 568-580, 2009.
173. J. Folkman, M. K. Klagsbrun, J. Sasse et al., "A heparin-binding angiogenic protein e basic fibroblast growth factor e is stored within basement membrane," American Journal of Pathology, vol. 130, no. 2, pp. 393-400, 1988.
174. W. Loilome,A.D. Joshi, C.M. J. apRhys et al., "Glioblastoma cell growth is suppressed by disruption of fibroblast growth factor pathway signaling," Journal ofNeuro-Oncology, vol. 94,no. 3, pp. 359-366, 2009.
175. S. Bao, Q. Wu, R. E. McLendon et al., "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response," Nature, vol. 444, no. 7120, pp. 756-760, 2006.
176. S.Miyamoto,H.Teramoto, O. A. Coso et al., "Integrinfunction: molecular hierarchies of cytoskeletal and signaling molecules," Journal of Cell Biology, vol. 131, no. 3, pp. 791-805, 1995.
177. B. M. Gumbiner, "Cell adhesion: the molecular basis of tissue architecture and morphogenesis," Cell, vol. 84, no. 3, pp. 345-357, 1996.
178. S. P. Palecek, J. C. Loftust,M.H.Ginsberg, D. A. Lauffenburger, and A. F. Horwitz, "Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness," Nature, vol. 385, no. 6616, pp. 537-540, 1997.
179. E. A. Clark and J. S. Brugge, "Integrins and sign transduction pathways: the road taken," Science, vol. 268, no. 5208, pp. 233-239, 1995.
180. A. P. Gilmore and L. H. Romer, "Inhibition of Focal Adhesion Kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation," Molecular Biology of the Cell, vol. 7, no. 8, pp. 1209-1224, 1996.
181. D. G. Stupack, X. S. Puente, S. Boutsaboualoy, C.M. Storgard, and D. A. Cheresh, "Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins," The Journal of Cell Biology, vol. 155, no. 4, pp. 459-470, 2001.
182. N. O. Fortunel, H. H. Otu, H. H. Ng et al., "Comment on "'stemness": transcriptional profiling of embryonic and adult stem cells' and 'a stem cell molecular signature'," Science, vol. 302, no. 5644, p. 393, 2003.
183. P. E. Hall, J.D.Lathia,M. A. Caldwell, andC. Ffrench-Constant, "Laminin enhances the growth of human neural stem cells in defined culture media," BMC Neuroscience, vol. 9, article 71, 2008.
184. K. Loulier, J. D. Lathia, V. Marthiens et al., "1 integrin maintains integrity of the embryonic neocortical stem cell niche," PLoS Biology, vol. 7, no. 8,Article ID e1000176, 2009.
185. F. Aloisi, G. Borsellino, P. Samoggia et al., "Astrocyte cultures from human embryonic brain: characterization and modulation of surface molecules by inflammatory cytokines," Journal of Neuroscience Research, vol. 32, no. 4, pp. 494-506, 1992.
186. W. Paulus, I. Baur, D. Schuppan, and W. Roggendorf, "Characterization of integrin receptors in normal and neoplastic human brain," The American Journal of Pathology, vol. 143, no. 1, pp. 154-163, 1993.
187. M.-C. Gingras, E. Roussel, J. M. Bruner, C. D. Branch, and R. P. Moser, "Comparison of cell adhesion molecule expression between glioblastomamultiforme and autologous normal brain tissue," Journal of Neuroimmunology, vol. 57,no. 1-2, pp. 143-153, 1995.
188. D. Vitolo, P. Paradiso, S. Uccini, L. P. Ruco, and C. D. Baroni, "Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread," Histopathology, vol. 28, no. 6, pp. 521-528, 1996.
189. J. D. Lathia, J. Gallagher, J. M. Heddleston et al., "Integrin alpha 6 regulates glioblastoma stem cells," Cell Stem Cell, vol. 6, no. 5, pp. 421-432, 2010.
190. M. Nakada, E. Nambu, N. Furuyama et al., "Integrin 3 is overexpressed in glioma stem-like cells and promotes invasion," British Journal of Cancer, vol. 108, no. 12, pp. 2516-2524, 2013.
191. M. Takeichi, "Cadherins in cancer: implications for invasion and metastasis," Current Opinion in Cell Biology, vol. 5, no. 5, pp. 806-811, 1993.
192. U. Cavallaro and G. Christofori, "Cell adhesion and signalling by cadherins and Ig-CAMs in cancer," Nature Reviews Cancer, vol. 4, no. 2, pp. 118-132, 2004.
193. B.M.Gumbiner, "Regulation of cadherin-mediated adhesion in morphogenesis," Nature Reviews Molecular Cell Biology, vol. 6, no. 8, pp. 622-634, 2005.
194. N. Cordes, B. Hansmeier, C. Beinke, V. Meineke, and D. van Beuningen, "Irradiation differentially affects substratumdependent survival, adhesion, and invasion of glioblastoma cell lines," British Journal of Cancer, vol. 89, no. 11, pp. 2122-2132, 2003.
195. S. Monferran, N. Skuli, C. Delmas et al., "v3 and v5 integrins control glioma cell response to ionising radiation through ILK and RhoB," International Journal of Cancer, vol. 123, no. 2, pp. 357-364, 2008.
196. N. Cordes, J. Seidler, R. Durzok, H. Geinitz, and C. Brakebusch, "1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury," Oncogene, vol. 25, no. 9, pp. 1378-1390, 2006.
197. K. S. Midwood and G. Orend, "The role of tenascin-C in tissue injury and tumorigenesis," Journal of Cell Communication and Signaling, vol. 3, no. 3-4, pp. 287-310, 2009.
198. M. Higuchi, T. Ohnishi, N. Arita, S. Hiraga, and T. Hayakawa, "Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis," Acta Neuropathologica, vol. 85, no. 5, pp. 481-487, 1993.
199. R. Riekki, A. Jukkola, A. Oikarinen, and M. Kallioinen, "Radiation therapy induces tenascin expression and angiogenesis in human skin," Acta Dermato-Venereologica, vol. 81, no. 5, pp. 329-333, 2001.
200. A. Leins, P. Riva, R. Lindstedt, M. S. Davidoff, P. Mehraein, and S. Weis, "Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma," Cancer, vol. 98, no. 11, pp. 2430-2439, 2003.
201. J. H. Uhm, N. P. Dooley, A. P. Kyritsis, J. S. Rao, and C. L. Gladson, "Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death," Clinical Cancer Research, vol. 5, no. 6, pp. 1587-1594, 1999.
202. C. L. Gladson and D. A. Cheresh, "Glioblastoma expression of vitronectin and the anb3 integrin: adhesion mechanism for transformed glial cells,"The Journal of Clinical Investigation, vol. 88, no. 6, pp. 1924-1932, 1991.
203. C. L. Gladson, J. N. Wilcox, L. Sanders, G. Y. Gillespie, and D. A. Cheresh, "Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors," Journal of Cell Science, vol. 108, no. 3, pp. 947-956, 1995.
204. K. Umezawa, S. Asakura, Y.-M. Jin, and M. Matsuda, "Localization of vitronectin-and fibronectin-receptors on cultured human glioma cells," Brain Research, vol. 659, no. 1-2, pp. 23-32, 1994.
205. P. G. R. Schmalz, M. J. Shen, and J. K. Park, "Treatment resistance mechanisms of malignant glioma tumor stem cells," Cancers, vol. 3, no. 1, pp. 621-635, 2011.
206. C. E. Eyler and J. N. Rich, "Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis," Journal of Clinical Oncology, vol. 26, no. 17, pp. 2839-2845, 2008.